Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could predict leukemia survival

NCT ID NCT04641910

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that these blood markers can separate patients into good, intermediate, and high-risk groups, which could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a better tool to predict which AML patients need more or less aggressive treatment.
What could go wrong
This is an observational validation study, not a treatment trial. It may confirm the approach works only in this specific group and not in others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

201 people

The number who actually took part.

Started

Jun 2021

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any newly diagnosed AML patients treated intensively in centres belonging to the FILO group will be eligible for the FLAMVAL study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years old * Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification (Arber et al., 2016) * Non previously treated AML (first-line therapy) * Patients eligible to standard 3+7 induction chemotherapy with a minimum of 3 days of daunorubicin at 45mg/m2/day or a minimum of 5 days of idarubicin at 8mg/m2/day and a minimum of 7 days of cytarabin at 100mg/m2/day * Patients receiving any "third drug" combined to the "3+7" scheme, i.e. lomustine, corticotherapy, elthrombopag, gemtuzumab-ozogamycin, any FLT3 inhibitors… are eligible * Patients receiving CPX-351 (Vyxeos ®) are eligible * Patients requiring leukapheresis are eligible * Signed informed consent Exclusion Criteria: * Patients diagnosed with Acute Promyelocytic Leukemia (AML-3) * Adults under guardianship, subjects under protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

Contacts and locations

Locations

  • AP-HP Cochin Hospital

    Paris, 75014, France

  • Angers University Hospital

    Angers, Maine-et-Loire, 49000, France

  • Basque coast hospital center

    Bayonne, Pyrénées-Atlantiques, 64102, France

  • Besançon University Hospital

    Besançon, Doubs, 25000, France

  • Bordeaux University Hospital

    Bordeaux, Gironde, 33076, France

  • Brest University Hospital

    Brest, Finistère, 29200, France

  • Béziers Hospital Center

    Béziers, Hérault, 34500, France

  • Clermont-Ferrand University Hospital

    Clermont-Ferrand, Puy-de-Dôme, 63000, France

  • Grenoble University Hospital

    Grenoble, Isère, 38000, France

  • Lyon University Hospital

    Lyon, Rhône, 69000, France

  • Mercy Regional Hospital

    Metz, Moselle, 57000, France

  • Montpellier University Hospital

    Montpellier, Hérault, 34295, France

  • Mulhouse Hospital Center

    Mulhouse, Haut-Rhin, 68100, France

  • Nancy University Hospital

    Nancy, Meurthe-et-Moselle, 54000, France

  • Nantes University Hospital

    Nantes, Loire-Atlantique, 44093, France

  • Nîmes University Hospital

    Nîmes, Gard, 30000, France

  • Paoli-Calmette Institute

    Marseille, Bouches-du-Rhône, 13000, France

  • Poitiers University Hospital

    Poitiers, 86000, France

  • Reims University Hospital

    Reims, Marne, 51100, France

  • Rennes University Hospital

    Rennes, Ille-et-Vilaine, 35033, France

  • Saint-Etienne University Hospital

    Saint-Étienne-de-Montluc, Pays de la Loire Region, 42000, France

  • Saint-Jean Hospital Center

    Perpignan, Pyrénées-Orientales, 66000, France

  • Strasbourg University Hospital

    Strasbourg, Bas-Rhin, 67200, France

  • Toulouse University Cancer Institute

    Toulouse, Haute-Garonne, 31000, France

  • Tours University Hospital

    Tours, Indre-et-Loire, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.